Turnstone Biologics Corp. (TSBX)
(Delayed Data from NSDQ)
$0.36 USD
+0.01 (1.43%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.36 +0.01 (1.41%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TSBX 0.36 +0.01(1.43%)
Will TSBX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TSBX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TSBX
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?
TSBX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TSBX
Turnstone Biologics to be acquired by XOMA Royalty
Turnstone Biologics (TSBX) Agrees to Acquisition by XOMA Royalty | TSBX Stock News
Xoma to acquire Turnstone Biologics for $0.34 in cash per share
Xoma to acquire Turnstone Biologics for $0.34 in cash per share
Turnstone Biologics Corp. Enters Merger Agreement with XOMA